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1. Introduction
Stem cells have enormous potential in health and medical research due to their ability to
differentiate into specialized cells and to self-renew. Applications can be seen in cell-based
therapies, e.g. for the treatment of Parkinson's disease, type I diabetes, arthritis, burn victims,
and cardiovascular diseases, as well as in tissue engineering of artificial organs, development
and testing of drugs, and in vitro toxicity tests [1-9].
In general, stem cells are cells generating identical daughter and progenitor cells, which both
have the ability to develop terminally differentiated functional cells after going through a
defined differentiation process [10,11]. There are two types of stem cells, varying in their ability
to differentiate, methods of isolation and propagation and, thus, their application potential:
embryonic stem cells and adult stem cells. Whereas embryonic stem cells represent pluripotent
cells which are able to grow into all derivatives of the three germ layers, adult stem cells are
only able to develop into a limited number of cells. Adult stem cells, to which mesenchymal
stem cells (also referred to as mesenchymal stromal cells) belong, are of postnatal origin, are
more tissue-specific, and regarded as multipotent. In this work the focus is laid on mesenchy‐
mal stem cells (MSCs) as they have become increasingly important in the field of regenerative
medicine in recent years. Numerous clinical studies have confirmed the safety of allogenic and
autologous MSCs for treatment of human diseases [12,13]. Currently, MSCs are being inves‐
tigated in terms of their therapeutic potential for inflammatory, autoimmune and degenerative
conditions in preclinical and clinical studies [14,15].
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Between the late 1960s and the 1980s, Friedenstein et al. [16-18] and Owen et al. [19,20]
described tissue-specific progenitor cells capable of differentiation to cells of mature tissues.
They worked with subpopulations of bone marrow cells characterized by osteogenic potential.
Interestingly, the term MSC was introduced in 1991 for the first time. Caplan [21] proposed
classifying adult stem cells as MSCs, if they were able to differentiate to all cells of mesodermal
lineage, although their multilineage potential was only demonstrated later by Pittinger et al.
[22] (for review see [23]). Between the 1990s and 2000s numerous studies were conducted with
cell populations that were, strictly speaking, not MSCs according to Caplan`s proposed
definition. Finally, as it became impossible to compare results, a revision of the MSC definition
was introduced by the International Society for Cellular Therapy (ISCT) in 2006 [24]. The ISCT
definition is based on two cellular properties of MSCs which are morphologically similar to
fibroblasts: (1) their adherence to plastic and (2) their trilineage differentiation to adipogenic,
chondrogenic and osteogenic cells [25]. Additional requirements include positive expression
of CD105 (endoglin marker), CD73 (ecto-5`-nucleotidase marker) and CD90 (Thy1 marker),
and negative expression of CD45 (leukocyte marker), CD34 (hematopoietic stem cell marker),
CD14 or CD11b (monocyte and macrophage markers), CD79 or CD19 (B cell marker), and
human leukocyte antigen class II.
As things stand, bone marrow aspirate represents the most often used source [22] of MSCs. In
addition, MSCs are obtained from adipose tissue [26], placenta as well as umbilical tissue [15]
and blood [27,28], and peripheral blood [29] (Figure 1). Other sources, such as periosteum,
trabecular bone, synovia, skeletal muscle, deciduous teeth, fetal pancreas, lung, liver and
amniotic fluid, have also been reported [15]. But independent of the source, the low frequency
of MSCs makes their direct collection for the majority of MSC applications unfeasible. A
therapeutic dose has been reported to range between 1 and 1000⋅106 cells per kg body weight
[30-33], whereby the exact dosage is determined by the type of disorder. However, when
expanding MSCs for particular therapies, the type of therapy (that is, either an allogeneic or
autologous one) also needs to be taken into account. In doing so, the ability of MSCs (which
display heterogeneous cell populations that vary from donor to donor and depend on donor
age and tissue) [34,35] to rapidly proliferate in vitro is exploited.
In order to fulfill the potential of MSCs as therapeutic agents for a wide range of applications,
culture conditions need to be optimized to obtain clinical grade MSCs with defined safety
standards at large scale [14,15,31,41-46]. To achieve this, strategies for preparation of the
required quantities of cells, have to be implemented, which allow the undifferentiated state to
be preserved or direct stem cell differentiation into the desired lineage. Scalable culture
systems with optimized culture strategies and controlled culture environment are prerequi‐
sites for the successful transfer of stem cell-based therapy concepts into clinical routine. In the
following, we describe the main characteristics of MSCs with respect to cultivation, appropri‐
ate cultivation methods for mass production, and a new scale-up-approach for expanding
human mesenchymal stem cells (hMSCs) derived from adipose tissue (hADSCs) and bone
marrow (hBM-MSCs).
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2. Characteristics of MSCs and the influence of the engineering parameters
on the cultivation
2.1. Main factors influencing MSC cultivation
For the successful expansion of stem cells appropriate culture conditions are essential. When
working with MSCs in vitro, the problems are non-infinite growth and non-complete directed
differentiation [47]. A critical step is the isolation of specific stem cells, as they often occur in
small quantities and only in a tissue formed by other cells. Therefore, special protocols for their
isolation and preservation are required [48]. Furthermore, in vivo stem cells live in a highly
specialized microenvironment. This microenvironment interacts with a number of character‐
istics such as the extracellular matrix surrounding the cells and mediators on growth and
differentiation. These factors have to be modeled for in vitro expansion by appropriate selection
Figure 1. Main sources and properties of MSCs. Today`s high pre-and clinical interest in MSCs is ascribed not only to
their multipotency, but also to their paracrine secretion of angiogenic factors, cytokines and immunomodulatory sub‐
stances, which is documented by a body of literature (e.g. [36-40]).
Mass Production of Mesenchymal Stem Cells — Impact of Bioreactor Design and Flow Conditions on Proliferation…
http://dx.doi.org/10.5772/59385
121
of the matrix for cell adhesion, the culture medium including growth factors, and the physical
environment, i.e. temperature, pH, oxygen and shear effects.
Self-renewal and the differentiation potential of stem cells are influenced to a large extent by
donor age and passage number [49,50]. In general, MSCs can be expanded by several orders
of magnitude in a few weeks [51] due to their high expansion potential. But with increasing
passage number they can lose their multipotency or their specific cell surface markers might
be downregulated, resulting in a loss of the therapeutic properties of these cells [52]. After 30
to 40 doublings MSCs become senescent, accompanied by inhibited growth and induction of
apoptosis [53]. It is assumed that this effect is induced to some extent by the harsh enzymatic
treatment during subcultivation, e.g. by trypsinization. Consequently, techniques without
subcultivation have been investigated to prolong the proliferation phase and to increase the
expansion factor [54]. Kretlow et al. [50] observed that both increasing age and the number of
passages have lineage dependent effects on MSC differentiation potential. In addition, there
seemed to be an interplay between donor age and cell passage number. These effects are of
high relevance for clinical therapies, because they might have strong impact on the cultivation
protocol.
As mentioned above, the extracellular microenvironment plays a significant role in controlling
cellular behavior. In recent years, different biomaterials have been studied to find a microen‐
vironment that is conducive to stem cell growth and differentiation, and that mimics the in
vivo situation, at least to some extent (reviewed by [55]). Appropriate biomaterials can support
the cellular attachment, proliferation, and lineage-specific differentiation of stem cells. In the
case of MSC differentiation growth factors or factors known to induce lineage commitment of
stem cells were incorporated into cultures with scaffolding materials, quite often for regulation
of osteogenic, chondrogenic or adipogenic differentiation [56-59]. Because such scaffolding
materials are not normally used for MSC expansion, they are not further discussed here.
For expansion with the final goal of harvesting large quantities of MSCs, they are typically
adhered to a surface with optimized surface chemistry and topography, which supports cell
attachment, spreading and proliferation (Figure 2). Today, routine cultivation of MSCs is
performed in planar plastic plates and flasks ensuring two-dimensional (2-D) growth [60].
Reusable glass systems are very seldom utilized at this time. As plates and flasks allow for a
limited expansion only and subcultivations exceeding 6 passages (see above) should be
avoided (high risk of cell differentiation), scalable matrices have been established. These
matrices cover hollow fiber membranes, macrocarriers [61,62] and, in particular, microcarriers
(see also Section 3).
Microcarriers are small spherical particles differing in core material, density, diameter and
surface charge, and are intended for use in suspension bioreactors. Table 1 gives an overview
of commercially available microcarriers that are suitable in MSC expansions. Depending on
the porosity, the microcarriers are classified into non-porous, micro-porous (pore sizes < 1 μm)
and macro-porous types (pore sizes between 10 and 50 μm). Whereas in non-and microporous
microcarrier cultures the cells attach to the surface of the beads, in macro-porous microcarrier
cultures they grow in the pores. However, cell harvest is more complicated, which is a general
challenge in microcarrier-based cultivations. While taking care to avoid differentiation or even
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damage, the cells are normally harvested after chemical treatment [63-65]. Examples of stem
cell proliferation on microcarriers can be found in [66-69].
Type Diameter
[μm]
Density
[kg·m3]
Surface area
[cm2·g-1]
Charge
[+/-]
Core material
CultiSpher-G 130-380 1020 - none Gelatin
CultiSpher-S 130-380 1020 - none Gelatin
Cytodex I 147- 248 1030 4400 + Cross-linked dextran
Cytodex III 141-211 1040 2700 none Cross-linked dextran
Collagen 90-150 / 125-212 1020 480 / 360 none Cross-linked polystyrene
FACT III 90-150 / 125-212 1020 / 1040 480 / 360 + Cross-linked polystyrene
Hillex II 160-180 1110 515 + Modified polystyrene
Hillex-CT 160-180 1110 515 + Modified polystyrene
Plastic 90-150 / 125-212 1020 / 1040 480 / 360 none Cross-linked polystyrene
Plastic Plus 90-150 / 125-212 1020 / 1040 480 / 360 + Cross-linked polystyrene
ProNectin F 90-150 / 125-212 1020 / 1040 480 / 360 none Cross-linked polystyrene
Glass 90-150 / 125-212 1020 / 1040 480 / 360 none Cross-linked polystyrene
Table 1. Overview of commercially available microcarriers for the cultivation of MSCs. Non-porous
microcarriers=Hillex II, Hillex-CT, Plastic, Plastic Plus, ProNectin F, Glass; micro-porous microcarriers=Cytodex I,
Cytodex III; macro-porous microcarriers=CultiSpher-G, CultiSpher-S.
Figure 2. Adherent glandular stem cells grown in a T-Flask (bar: 500 μm).
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An alternative is carrier-free cultivation in 3-D (three-dimensional) aggregates or spheroids,
or encapsulation, e.g., in alginate [70] or in hydrogels [57,71-79]. These techniques are often
used to induce a lineage specific differentiation. With respect to the expansion of MSCs, there
is conflicting evidence in the literature with regard to the usefulness of these techniques.
Detrimental effects such as altered proliferation, stem cell marker expression, cell shape and
modified differentiation potential have been reported [80,81]. A general problem in 3-D
aggregates can be seen in the inhomogeneous supply of oxygen and nutrients. Therefore, it is
unlikely that carrier-free cultivation of MSCs is an appropriate approach for the standardized
production of large quantities of cells with consistent product quality.
A further strong impact on MSC proliferation and differentiation is exerted by the culture
medium through its composition (content of nutrients such as glucose or glutamine, growth
factors, type and concentration of serum), culture conditions such as pH or oxygen concen‐
tration, and the density, in which the cells were plated/seeded [47].
Due to the importance of hyperglycemia in vivo and the hypothesis, that high glucose could
be deleterious to stem cell therapy, the impact of glucose on proliferation, potential for
differentiation, and other physiological effects have been studied intensively. Glucose
concentration in basal media has been shown to have both positive and negative impacts on
MSC growth [47,82-93]. It is beyond the scope of this chapter to discuss the various effects in
detail but certain findings are presented below to highlight the complexity of this topic:
• Evidence of retention of MSC characteristics from different sources with regard to surface
marker profiling, proliferation, differentiation and karyotyping when cultured extensively
in DMEM-HG medium containing a high glucose concentration of 25 mM [83].
• Increase in peak cell density by 40 % at low glucose concentration (5.5 mM) when compared
with an expansion at high glucose concentration (25 mM) [84].
• High glucose concentration in cell culture medium did not acutely affect hMSC growth
factor or proliferation [88].
• High glucose (25mM) enhanced telomerase-immortalized human mesenchymal stem cell
(hMSC-TERT) proliferation in long-term studies in contrast to hMSCs, where proliferation
was unchanged. Thioredoxin-interacting protein, which is involved in apoptosis regulation,
was stimulated by glucose in hMSC-TERT. However, in both cell types apoptosis was not
influenced by high glucose levels [90].
• Culture in high glucose-containing medium had a negative effect on colony formation and
differentiation for rat non-adherent bone marrow MSCs [91].
• Glucose reduction prevents replicative senescence and increases mitochondrial respiration
in hMSCs [94].
• High glucose conditions suppress the function of bone marrow-derived endothelial
progenitor cells via inhibition of the eNOS-caveolin-1 complex [82].
• High glucose regulates cyclin D1/E of hMSCs through TGF-beta1 expression via Ca2 /PKC/
MAPKs and PI3K/Akt/mTOR signal pathways [92].
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It seems that MSCs are affected by high glucose concentrations. However, in respect of
proliferation and differentiation, no real advantage of low glucose concentrations has been
found to date. Our own data (not published) indicate that the effect of high glucose concen‐
trations on MSC-fate depends to a large extent on the medium formulation, e.g. the type and
concentration of serum or growth factor concentration (see also below). For practical reasons,
cultivation at high glucose levels has some advantages, as in low glucose media more frequent
medium-feeding or exchange is required than at higher cell densities.
The impact of glutamine has been studied less extensively than that of glucose. Ferrari et al.
observed an increase in peak cell density by approx 25 % when adding of 2 to 6 mM of
glutamine [84]. Schop et al. concluded from their studies that glutamine has no importance as
an energy source for hMSCs [93].
In the cultivation and differentiation of stem cells, growth factors play an important role. They
influence self-renewal, senescence, aging, embryonic development and differentiation [95].
Thus, they create an appropriate microenvironment and provide important messenger signals
for cells. In effect, growth factors can induce or inhibit signaling cascades in the cells via
receptors on the cell surface which affect cell physiology [96]. In many types of stem cells,
regulation of self-renewal is done by proteins of the fibroblast growth factor (FGF)-family [95].
For example, for FGF-2 an improved expansion was demonstrated [97]. The absence of
aforementioned growth factors may lead to differentiation of stem cells, which is unwanted
in the pure propagation of the cells [98]. Again, the appropriate concentration of growth factors
needs to be determined depending on the cells, medium composition etc. [99].
A further important medium compound with respect to stem cell physiology is serum, in
particular its type and concentration. At present, most studies are performed using fetal calf
serum (FCS) or fetal bovine serum (FBS) in concentrations between 10 % and 20 % [100]. In
Section 5 an example with reduced FBS concentration is discussed. Clinical studies require a
GMP- compliant medium [43,101] due to the drawbacks of serum (non-human origin, possible
contamination etc.) [102]. Although human serum has positive effects compared to FCS or FBS,
extended use for large scale processes is doubtful due to limited availability. Replacement of
serum containing medium by serum-free medium formulation has been addressed by a
number of publications during the last few years [103-113]. The first serum-free culture media
(for example StemPro® MSC SFM XF) for MSCs are now commercially available. However,
the cultivation results (cell yields) have not proved satisfactory and the matrix is generally
being pre-coated with serum [114,115].
Hypoxic conditions are regarded as advantageous for stem cell proliferation and differentia‐
tion. MSCs grown in vitro with reduced oxygen content in the gassing air were characterized
by increased cell proliferation. It has been shown that at 1% and 5% oxygen in the gassing air
the cells enter the exponential growth phase earlier and produce less inhibitor substances
[114,116]. Our own studies (data not published) underline this, but indicate that with an
optimized medium the positive effect of low oxygen concentration seems to be smaller. Further
culture parameters such as osmolality, pH and temperature might influence stem cell fate, but
these parameters have not yet been studied intensively so far.
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For large scale expansion of MSCs, the cell density required for seeding has a strong impact
on the expansion capacity. Due to restricted availability of the cell material and limited
population doubling or passage number, the lowest possible seeding density of cells should
be applied [51,117]. Fortunately, the literature data suggest that seeding MSCs at low densities
(2.5 instead of 2500 cells cm-2) can increase cell proliferation and cell density while maintaining
marker profile [118]. Colter et al. seeded 1.5 and 3.0 cells cm-2 and successfully generated single
cell-derived colonies [51]. Hewitt et al. [119] found the best conditions for cell expansion on
microcarriers to be 3000 microcarriers mL-1 (ca. 1 g dry weight L-1) in flasks. They determined
a seeding density of 5 cells per microcarrier. Higher growth rates of MSCs seeded at lower
densities are explained by a longer exponential growth phase, more population doublings,
and more availability of nutrients per cell [120].
2.2. Shear stress and the influence of engineering parameters on MSC proliferation and
differentiation
2.2.1. General basics
There is strong evidence that growth and differentiation of stem cells are effected by several
types of mechanical forces including stretch, strain, compression, and shear stress [121]. Due
to the importance of shear stress, the fundamentals are given in this section before shear effects
on expansion of MSCs are discussed.
Cells growing adherent to a solid matrix are exposed to shear forces from the moving fluid.
By definition shear in a fluid system has two components, shear stress τ and shear rate γ. Shear
stress is a force per unit area acting on and parallel to a surface. Shear rate is a measure of a
velocity gradient (velocity/length). The two quantities are therefore related in laminar
Newtonian fluid - and cell culture media are regarded as Newtonian - by
flt h g= × (1)
where ηfl is the viscosity of the fluid. In model systems such as laminar flow between two
parallel plates, cone-and-plate viscometer or a coaxial cylinder Searle viscometer, the shear
rate and corresponding shear stress can be calculated by simple mathematical equations. Shear
effects are often investigated in flow chamber bioreactors consisting of parallel plates [122]. In
this apparatus, a laminar flow causes a defined wall shear stress τw on the bottom plate where
the cells grow adherently (see Figure 3). The shear stress for a Newtonian fluid at a surface
element parallel to a flat plate at the point y is given by
fl
dU
dyt h
æ ö= × ç ÷è ø (2)
where U is the velocity of the fluid along the boundary and y is the height above the boundary.
Specifically, wall shear stress is defined as:
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    y=0w fl dUdyt h
æ ö= × ç ÷è ø (3)
Flow velocity U(y) can be calculated for given values of the flow rate F, the height h and the
width b of the flow chamber (Figure 3):
( )236( ) FU y h y yb h= × × -× (4)
Wall shear stress τw acting on the cells is given by:
2
6   y=0 =  
fl
w fl
FdU
dy b h
ht h æ ö= × ç ÷è ø (5)
Figure 3. Wall shear stress acting on adherent cells in a flow chamber with parallel plates. For abbreviations see text
(modified from [122], with kind permission from Springer Science and Business Media).
In the complex, mostly turbulent environment in a culture system (bioreactor), the local shear
rate varies within the vessel and it therefore is more difficult to associate cellular effects (cell
damage, differentiation etc.) with the magnitude of the prevailing shear rate or the associated
shear stress. An example is given in Figure 4 for cells grown on microcarriers in suspension,
e.g. a spinner flask, a stirred bioreactor or a wave-mixed bioreactor (see Section 3).
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Figure 4. Shear forces on microcarriers in a turbulent flow. Microcarrier-eddy interactions: (a) eddies much larger than
beads, (b) multiple eddies the same size as beads, (c) eddies the size same as interbead spacing.
Several concepts to describe the complex shear effects on cells in a turbulent flow were de‐
scribed and evaluated with available data in respect of the impact of shear forces on micro‐
carrier cultures in bioreactor systems (reviewed in [122]). Among others, the concept of an
"Integrated Shear Factor" ISF – a measure of the strength of the shear field between the im‐
peller and the spinner flask walls – was developed to describe shear damage to continuous
mammalian cell lines [124]. For a stirred bioreactor, the ISF is given by
2   R R
R R
n dISF D d
p= - (6)
with rotational speed nR, vessel diameter DR and impeller diameter dR. According to Cherry
und Papoutsakis [123] the largest shear stress to which cells grown on microcarriers are
exposed occurs in turbulent eddies which are the same size as the microcarriers. The energy
of the eddies is transferred to the surface of the microcarriers, resulting in high local velocity
gradients between the microcarriers and the fluid, and the highest shear rates on the cells. The
microcarriers are caused to rotate within these eddies. Using Kolmogorov´s theory the length
scale lKol of the smallest eddies are in the order of
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Koll ne
æ ö= ç ÷ç ÷è ø
(7)
where ν is the kinematic viscosity and ε the energy dissipation rate per unit mass
fl L
P
Ve r= (8)
with power input P and liquid volume VL. The Kolmogorov eddy length scale corresponds to
the diameter of the smallest eddy generated in the bioreactor. In a turbulent environment,
eddies break down to form smaller eddies. On the Kolmogorov length scale, viscosity
dominates and the turbulent kinetic energy is dissipated into heat. When the Kolmogorov eddy
length scale becomes equivalent to the diameter of the microcarrier, movement of the flow
lines can shear the cells. The Kolmogorov eddy length scale is affected by stirrer speed, liquid
properties and impeller design. Croughan et al. [125] used this concept to describe cell damage
in respect of cells grown on microcarriers. Damage became significant when the microscale
was about two-thirds the size of the microcarriers, or smaller (discussed by [119]).
Besides the above-mentioned concept for estimation of shear stress in bioreactors, several
numbers are used to characterize culture systems (bioreactors) such as (1) geometric dimen‐
sions, (2) volumetric power input (P/V), (3) power number (Newton number, Ne), which is
defined as
3 5  R R fl
PNe n d r= (9)
for stirred bioreactors (with rotational speed nR and fluid density ρ), (4) volumetric mass
transfer coefficient (kLa) for oxygen or CO2, (5) mixing time, (6) Reynolds number, which is
given by
2
Re fl R R
fl
n dr
h= (10)
for stirred bioreactors, (7) impeller tip speed (utip) for stirred bioreactors, and (8) volumetric
gas flow, among others. These numbers can be used to compare process parameters in different
bioreactor systems. Recommendations for determination of these parameters have been
published by [126] and [127], for example.
The numbers introduced above are not usually suitable for a more in-depth description of fluid
flow in a bioreactor. This can be accomplished by computational fluid dynamic (CFD)
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simulations [128-130]. CFD uses numerical methods and algorithms to solve and analyze
problems that involve fluid flows. This is especially important for tissue engineering con‐
structs, in which a set of complex phenomena such as hydrodynamics, nutrient transfer, cell
growth, and matrix deposition have to be taken into account [131-133]. Parameters such as
fluid velocity, oxygen tension, stress, and strain, which are difficult to determine experimen‐
tally, can be derived from CFD simulations and related to cellular parameters [132]. This is
advantageous for complex culture systems, where it is impractical or almost impossible to
install probes to determine fluid specific parameters (see Section 5).
2.2.2. Shear stress in MSC cultivations
Flow-induced shear stress can be stimulating or detrimental to the behavior of MSCs. In the
following, firstly a brief review of basic studies is given. These studies were mostly intended
to induce a lineage-specific differentiation of stem cells in which the main goal is to engineer
a microenvironment for controlled stem cell differentiation [134-136]. Secondly, the impact of
shear on stem cells grown in bioreactors for mass cell production is discussed.
2.2.2.1. Effects of shear stress on stem cell fate
Shear stress can affect stem cells in different ways [137,138], e.g. with respect to morphology,
proliferation capacity, gene expression, cell cycle arrest and apopotosis, proteomic profiling,
and differentiation [139-147]. In some cases opposing conclusions have been reported. Adamo
and Garcia-Cardena [139] as well as Chang and Wang [140] observed changes in the cell
morphology of MSCs due to shear stress (e.g., differences in morphology between static and
dynamic culture systems). Changes in morphology can have an influence on cell proliferation
potential, as shown in earlier studies by Prockop and coworkers [142]. They reported that
smaller agranular cells divided faster than large granular cells, while the doubling time and
the differentiation potential remained the same. These results are contrary to those of Luo et
al. [143] and Maul et al. [144], who found that shear stress does not support cell proliferation,
but leads to cell cycle arrest or a decrease in cell number.
Numerous reports have addressed the induced differentiation of MSCs by shear stress [137],
mostly osteogenic [138,148-154] and chondrogenic [155,156]. Meanwhile, a suitable bandwidth
for shear effects on MSCs has been determined. In general, increasing shear stress seems to
promote osteogenesis and mineralization [137], but some of the findings are again contradic‐
tory. This is explainable to some extent through the different cultivation systems or bioreactors
used. Studies on the effect of shear forces were performed in either 2-D cultures (flow cham‐
bers) with defined shear stress or in perfused macroporous carriers [157]. While in two-
dimensional flow chambers (cell growth as monolayer) shear stress levels of 0.5-2 Pa are
required for stimulation of osteoblasts [151], which is in the order of the postulated Weinstein
shear forces of 0.8-3 Pa in the Haversian channels [158], the results are not readily transferable
to 3-D systems. 3-D bioreactors with perfusion or rotational motion (see Section 3) also show
the influence of flow on the osteogenic differentiation of osteoblastic cell lines, primary
osteoblasts and osteoblast precursor cells [159-163]. However, the calculated shear stresses
were in part up to 2-5 orders of magnitude below the values of the 2-D flow chambers. For
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greater understanding of effects in scaffolds, computer-based simulations are increasingly
used to detect the magnitude of shear forces [164,165]. The shear stress acting in the scaffolds
is usually in the range of a few mPa. However, this is often not caused by the local shear forces
acting on the cells, which are ultimately the important ones, but by those in the bulk flow.
Furthermore, it is rarely taken into account that in the various perfusion bioreactors not only
the perfusion rate for the development of local flow and shear forces is important, but also
matrix properties such as porosity, pore size, interconnectivity of the pores, and elasticity and
extensibility of the relevant material [162,166,167]. Moreover, with respect to tissue engineer‐
ing, fluid dynamic calculations are rarely coupled with mass transfer effects. In principle, it
cannot therefore be excluded that the effects observed are not due to a mechano-stimulation
of the cells, but to improved mass transport. Furthermore, different culture conditions such as
medium composition, type of serum, oxygen concentration etc. might also play a role (see
above).
2.2.2.2. Effect of shear stress on stem cells grown in bioreactors for cell expansion
For high level expansion of stem cells, bioreactor cultivations are required that support the
required number of cells. This involves minimal variations in lineage specific differentiation
while the genetic and epigenetic stability of the cells needs to be kept under control [132]. In
order to ensure this, the environment acting on the cells in a bioreactor needs to be character‐
ized and kept similar during upscaling of the process. To date, microcarrier-based suspension
cultures have been studied mostly for expansion of stem cells (see above) as they provide a
sufficient surface area for attachment and expansion [119,168]. Microcarriers are preferably
suspended in stirred bioreactors (see Section 3.2), where shear-influenced stem cell differen‐
tiation and shear-induced cell damage can be distinguished. The damaging effects of flow
stress in microcarrier cultures were studied in the 1980s and 1990s mostly in relation to
permanent or established cell lines [124]. Recent publications show that stem cells are affected
by shear stress below damaging levels (reviewed by [132]). With respect to cell expansion,
preferably without significant unwanted differentiation, a narrow band of shear stress levels
is essential [169]. Turbulent flow in stirred bioreactors, however, represents a scenario that is
not characterized by a narrow band of shear stress levels. The effect of broadband stresses
associated with turbulence in stirred bioreactors on preservation of the differentiation
potential of stem cells and minimization of lineage commitments is still poorly understood
[119,132,170-172]. Furthermore, controversial observations on the shear stress tolerance of the
cells might be due to protective substances contained in the medium, such as serum or
differences in the type of surface or cell density. Thus, for example, cells grown in the pores
of macroporous carriers are better protected against shear than cells grown on non-porous
carriers [63,67,173].
To summarize, on the one hand shear stress can be deliberately used for targeted differentia‐
tion of stem cells. On the other hand, with respect to stem cell expansion, shear effects need to
be minimized to prevent an unwanted differentiation. Therefore, in order to optimize process
design, the specific task of the cultivation or the target product should always be kept in mind.
During production of cell therapy products, cell expansion and harvest are in the foreground,
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and cell differentiation is generally undesirable. In the discussion that follows, the focus is
placed on epansion of MSCs and suitable bioreactors for cell therapy. Based on a classification
of the power input type and operating principles, the most common bioreactors are presented
and cultivation results are discussed.
3. Bioreactor systems for cell therapeutics
3.1. Classification
Since the early 2000s successful MSC expansions have been reported. In addition to static
bioreactors (Figure 5 A), different types of dynamic bioreactor versions (Figure 5 B) have
proven themselves. 2-D cultivations performed in planar systems such as petri dishes, T-flasks,
and stacked plate systems are still predominant in both the development and production of
cell therapeutics. Stacked plate systems (e.g., CellSTACKs®, CellFactories) with 10-or 4-layer
vessels are typically made of polystyrene and are non-instrumented, and have become the
system of choice in semi-commercial and commercial production processes [31,174]. Their
mass and energy transfer is exclusively caused by conduction and reaction processes within
the planar system and by interaction with an environment that is typically temperature and
humidity controlled. In other words, gas exchange only takes place at liquid-gas interphase
and concentration gradients can appear during cultivations. Not surprisingly, culture broth
inhomogeneities, which influence cell yield and quality, increase as the number of layers in
the vessel rises. Moreover, manipulations become more complicated and risk of contamination
also increases. In spite of additional attempts to apply robotics and bioreactor control to static
bioreactors [175,176], dynamic bioreactors ensuring 2-D or 3-D cell growth remain superior.
In dynamic bioreactors the power input generated is responsible for mass and energy transfer.
To date, a high number of different dynamic bioreactors have been used to expand MSCs.
According to the type of power input, they can be divided into mechanically driven, pneu‐
matically (air-) driven and hydraulically driven systems. Mechanically driven bioreactors
include stirred systems (Section 3.2), wave-mixed systems (Section 3.3), and a recently
introduced rotating bed bioreactor (Section 3.4) [177]. In actual fact, rotating bed (or wall vessel)
bioreactors [177,178] are important for tissue engineering applications aimed at cell differen‐
tiation (and not at cell expansion). Pneumatically driven versions such as the 3 L Air-Wheel
bioreactor from PBS Biotech® [179] are excluded, although a poster presentation on Coronado
Island recently showed that this bioreactor shows even slightly higher cell expansion rates
than a stirred system in MSC expansion runs. More often used are hydraulically driven
representatives, which include parallel plate bioreactors (Section 3.5), hollow fiber bioreactors
(Section 3.6), and fixed bed bioreactors (Section 3.7), for which power input is generated by
pumps.
In the case of the mechanically driven bioreactors, microcarriers (Section 2.1) or perfused plates
have so far provided the growth surface for the MSCs. In hydraulically driven bioreactors the
cells are grown either on perfused plastic surfaces (Section 3.5), hollow fibers (Section 3.6) or
packed particles (Section 3.7). It is worth mentioning that the majority of dynamic bioreactor
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types were originally developed for production processes aimed antibodies and vaccines. For
this, genetically modified, continuous mammalian cell lines such as Chinese hamster ovary
(CHO) cells are generally grown [180-182]. With the exception of spinner flasks (as simple
stirred bioreactors), mechanically driven bioreactors are generally instrumented with sensors
to enable monitoring and control of temperature, pH value, DO and carbon dioxide concen‐
tration, gas and liquid flow rates, impeller or rocking speed.
A second classification trial is based on the number of uses of the bioreactor`s cultivation vessel
and distinguishes between reusable and single-use bioreactors. Whereas the vessel of a
reusable bioreactor is made of glass or stainless steel, single-use bioreactors have a plastic
cultivation vessel. This cultivation vessel is pre-assembled, beta-or gamma-irradiated and,
then delivered as ready-to-use. After one use, as the vessel is a rigid polystyrene or polycar‐
bonate container or a flexible multilayer bag with contact layers made of polyethylene or
ethylene vinyl acetate, it is discarded [183]. For this reason single-use bioreactors are also often
referred to as disposable bioreactors. If single-use bioreactors are operated correctly for the
production of high value products at small and medium volume scale (as is the case for
productions of cell therapeutics), they contribute to savings in time and costs. Furthermore,
process flexibility and safety can be increased, which is an advantage in processes where the
cells produced are the target product that is directly given to the patient.
Different authors have described adverse effects on CHO cells grown in polyethylene bags
[184-188]. They found poor cell growth arising from leachables such as bis(2.4-di-tert-butyl‐
phenyl)phosphate. Such leachables are substances that can migrate from bag layers during
processing and leach out into the culture broth in concentrations that are deleterious to cell
growth. This phenomenon has not been reported for MSC expansions to date.
There is no doubt that advantages currently prevail if an appropriate single-use bioreactor
(regardless of whether it represents a static or dynamic system) is applied for productions of
cell therapeutics. This, together with the suitability of single-use bioreactors for commercial
production processes with Good Manufacturing Practice (GMP) and regulatory demands,
explains their increasing usage. In particular, dynamic systems including stirred, wave-mixed,
parallel plate, hollow fiber and fixed bed single-use bioreactors are currently the focus of
interest for producers of cell therapeutics.
3.2. Stirred single-use bioreactors in microcarrier-based MSC expansions
In stirred single-use bioreactors, mixing is induced by the mechanical agitation of one or more
impellers. For research purposes disposable spinner flasks operating with magnetically driven,
slowly moving paddle impellers (60 rpm) are most often used [189]. The cells are propagated
on microcarriers until working volumes of 250 mL. In contrast to scalable, automated stirred
bioreactor versions, spinner flasks are only surface-aerated. Furthermore, spinner cultivations
entail availability of incubators for temperature as well as humidity control. Nevertheless, peak
viable cell densities of between 6⋅105 and 1⋅106 cells mL-1 and maximum cell expansion factors
between 30 and 50 are achievable in spinner flasks when the culture medium contains serum
and is cyclically perfused (by manual partial and periodical medium exchange). This was
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demonstrated for hADSCs and hBM-MSCs expanded on polystyrene-and gelatin matrix based
microcarriers in our lab over a cultivation period of 7 days.
At benchtop scale MSC expansions were successfully carried out in the Mobius® Cell Ready
3L bioreactor (Merck Millipore) and the BIOSTAT® UniVessel 2L SU (Sartorius Stedim
Biotech). The key element of both systems is the rigid polycarbonate vessel, contains one or
Figure 5. Suitable bioreactors for MSC expansion. Presented classification bases on the power input type.
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two rotating impellers and an aeration device (sparger). The user can choose between plastic
vessels having reusable or single-use temperature, DO and pH probes.
The Mobius® CellReady bioreactor (maximum working volume of 2.4 L) is equipped with a
single top-driven marine impeller and an open pipe or micro-sparger. According to its
configuration, the main bioengineering parameters were investigated and summarized by
Kaiser et al. 2011 [190]. The published results of the bioengineering studies with the Mo‐
bius® CellReady 3L show that this system is also usable for MSC expansion. Suitable impeller
speeds are adjustable, which enables culture homogeneity while avoiding microcarrier
sedimentation, cell differentiation and cell damage that may result from too high shear stress.
For hBM-MSCs the accuracy of this hypothesis was demonstrated by the studies of Cierpka et
al. [191] and Jing et al. [192]. In cultivations running in serum-supplemented medium (10 %
FBS) for between 12 and 14 days, peak viable cell densities between 2.5⋅105 and 2.7⋅105 cells
mL-1 were obtained. Moreover, Stadler [193] and Ott [189] achieved a serum-reduced expan‐
sion of hADSCs within 6 days, which was comparable to a 250 mL reference spinner flask (100
mL working volume). In spite of reduced cultivation time and serum content, the peak viable
cell density was more than double (5.5⋅105 hADSCs mL-1) when compared with the results of
Cierpka et al. [191] and Jing et al. [192].
The top-driven UniVessel® SU 2L bioreactor (maximum culture volume of 2 L) has two 3-
segment blade impellers and an L-shaped macro-sparger. Similarly to the Mobius® Cell Ready
it is hydrodynamically well-characterized [194,195]. Peak viable cell densities between
1.8⋅105 hBM-MSCs mL-1 and 3⋅105 hADSCs mL-1 were determined in serum-supported
production processes on cultivation day 9 [189,196]. In order to increase MSC expansion
efficiency in the UniVessel SU 2L, Jossen et al. [197] improved the fluid flow while reducing
fluid shear stress for cultivations with higher microcarrier amounts. This was accomplished
by modifying the standard vessel design (increasing impeller blade angle from 30° to 45° and
reduction of off-bottom clearance from 0.41 to 0.26). As a result, the maximum specific power
input was reduced by a factor of 2 and the peak viable cell density was more than 3 times
higher than that of the hBM-MSCs, for which a cell expansion factor of 35 was reached.
Recently, the propagation of hADSCs on microcarriers in stirred bag bioreactors exceeding
benchtop scale was carried out for the first time. Schirmaier and coauthors [196] worked with
Sartorius Stedim`s top-driven BIOSTAT® CultiBag STR 50L, for which there is comprehensive
bioengineering characterization [195]. They used the 3-D bag version shown in Figure 7 E
(Section 5), in which two 3-segment blade impellers and a micro-sparger have been imple‐
mented. Cultivation was executed with 35 L working volume while realizing a partial medium
exchange on day 4. Growth on polystyrene microcarriers at serum-reduced conditions (in this
case, 5%) allowed 3⋅108 hADSCs to be harvested on cultivation day 9. This provided the basis
for the scale-up approach explicated in Section 5.
3.3. Potential of wave-mixed bioreactors for microcarrier-based MSC expansions
MSC expansions have already been carried out in wave-mixed bioreactors, which have a
pillow-like culture bag with single-use sensors for temperature, pH and DO control. The bag
is fixed on the rocker platform, which makes a one-dimensional (1-D) oscillatory movement.
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By rocking the platform a wave is induced in the bag, which contains medium and cells. In
this way, the medium surface is continuously renewed while bubble-free oxygen is introduced
into the culture broth from the headspace of the bag. Wave generation and propagation, and
thus mass and energy transfer, in this bioreactor type are dependent on the rocking rate,
rocking angle, aeration rate, filling level (50% maximum) and culture broth viscosity. These
parameters affect the fluid flow, mixing time, oxygen mass transfer, shear stress acting on cells,
and finally the cultivation result. As discussed by Eibl et al. [198] and Werner et al. [199], shear
stress is highest at the lowest filling level together with the highest rocking rate and rocking
angle. Indeed, energy dissipation and shear stress pattern were more homogeneous in wave-
mixed bioreactors with 1-D motion than in stirred cell culture bioreactors with a paddle
impeller. For this reason, these wave-mixed bioreactors are well-suited for productions with
shear sensitive cells. A further advantage of wave-mixed bioreactors is their negligible
foaming, meaning that there is no need for antifoam agents to be added, which also simplifies
downstream processing of the product. In addition, protocols for microcarrier-based produc‐
tions with different continuous mammalian cell lines are available as well as for primary cells
known to be very sensitive to shear and difficult to culture (such as T-cells) [200-204].
The first attempts published demonstrate the feasibility of expanding MSCs in 2 L wave-mixed
bags on Cytodex 3-and Cultispher-S-microcarriers. Akerström [205] propagated MSCs over
18 days while feeding carriers on day 11 and 13 into a Wave Bioreactor 2/10 (GE Healthcare).
The expansion factors determined after trypsinization were around 6. Timmins et al. [206]
achieved expansion factors around 16 on cultivation day 7 when producing MSCs derived
from the placenta at reduced O2 levels (5%). He published a procedure which was realizable
in wave-mixed bioreactors from both GE Healthcare and Sartorius Stedim Biotech.
3.4. Single-use rotatory bed bioreactors
An interesting new approach for a perfused dynamic bioreactor represents Zellwerk´s rotating
bed bioreactor system ZRP [177]. As shown in Figure 6, a cylindrical culture vessel has a
rotating bed of polycarbonate plates. Bed rotation is caused by a non-contact magnetic drive
coupled to the culture vessel. The culture vessel is equipped with sampling ports and a
measuring device with ports for pH and DO sensors. The external media circulation combined
with the rotation of the polycarbonate bed ensures mixing of the culture medium. To provide
an oxygen supply, the overlay atmosphere of the headspace of the vessel is aerated with CO2,
N2 and air. All cultivation parameters such as pH, DO, temperature and bed rotation are
monitored online and regulated by a control unit. Reichardt et al. demonstrated a 39 fold
expansion of cells derived from human umbilical cord arteries in 9 days [177].
3.5. Single-use parallel plate bioreactors
Whereas stirred and wave-mixed bioreactors used for the expansion of MSCs are operated
with microcarriers in fed batch mode (feeding or partial medium exchange), parallel plate
bioreactors run carrier-free and in continuous perfusion mode. Single-use parallel plate
bioreactors have a modular multiplate design. The plates are typically made from polystyrene,
whereby each plate consists of two compartments separated by a gas-permeable membrane
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(that is impermeable to liquids) [207]. Whereas the upper compartment is filled with air, the
bottom compartment contains the cells. The cells grow on the plastic surface of the bottom
compartment as monolayer (2-D growth) while being continuously supplied with culture
medium.
In general, plate bioreactors have been well-investigated in terms of shear stress, which is
regarded to be low in their case. In 1996 Peng and Palsson [208] studied the influence of their
geometry on fluid flow and the resulting growth and differentiation of bone marrow-derived
stem cells. They found a superiority of radial flow and ascribed this finding to the uniform
environment caused by the hyperbolic velocity and tube-like shear stress contribution. Due to
the absence of walls in the flow path and the location of the boundary walls parallel to the flow
direction, slow flowing regions were obtained on the growth surface of radial flow-type
parallel plate bioreactors.
Prominent representatives of single-use parallel plate bioreactors are Corning`s E-Cube™
System and Pall`s Integrity™ Xpansion™ Multiplate Bioreactor. The E-Cube, which is
available with 10-or 25-stack modules requires an incubator for operation. It offers a maximum
growth surface of 21,250 cm2. The Integrity™ Xpansion Multiplate Bioreactor is a self-
contained bioreactor system that is obtainable with 10 up to 200 plates and provides a
maximum growth surface of 122,400 cm2. Its gas exchange is realized in a central column with
channels along the plates through which the medium circulates. CFD studies realized with the
Integrity™ Xpansion™ Multiplate Bioreactor revealed the occurrence of gentle laminar flow.
Maximum wall shear stress did not exceed 10 mPA, which was up to 1000 times lower than in
stirred bioreactors (personal communication W. Kuhlmann, ATMI Life Sciences, June 2013).
Figure 6. The rotating bed bioreactor system. The bioreactor system is composed of a cylindrical culture vessel and an
integrated bed of polycarbonate plates with a cell culture surface area of up to 6000 cm2 (with courtesy of Zellwerk
Gmbh; Oberkrämer, Germany).
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Bone marrow-derived MSCs have been successfully expanded without differentiation in this
single-use bioreactor type, which generally allows production of up to a billion cells per batch.
By using holographic microscopy in cultivations with the Integrity™ Xpansion™ Bioreactor,
cell morphology can be monitored on the 10 top plates. Normally, the lack of opportunity to
monitor cells is regarded as a drawback of parallel plate bioreactors [209].
3.6. Hollow fiber bioreactors in MSC expansion procedures
Similarly to parallel plate bioreactors, hollow fiber bioreactors provide a low shear stress
environment [210] and cell propagation in continuous perfusion mode. Hollow fiber bioreac‐
tors are characterized by a high surface area-to-volume ratio (100-200 cm2 mL-1) and create 3-
D environment for cells. They consist of a bundle of parallel hollow fibers constructed from
cellulosic, polysulfone, polypropylene or polyethylene materials, which are encased in a
cylindrical polycarbonate cartridge with ports for flow around the fibers. The pore size of the
semi-permeable hollow fiber membrane determines which molecular species are rejected.
The beginning of hollow fiber technology dates back to the early 1970s [211], when Knazek
and his team used tubular membranes upon which cells were able to expand to high cell
densities (107 to 108 cells mL-1) and which were impermeable to the cells. Analogically, the fiber
matrix was permeable to gases, nutrients and metabolic waste products. Cells suspended in
the culture medium settled on the outer surfaces of hollow fibers while oxygenated culture
medium flowed continuously through the fibers. Medium nutrients diffused through the fiber
wall into the cells and metabolic waste products diffused from the cells through the fiber wall
into the perfused liquid.
Since then, hollow fiber bioreactors have been improved and used extensively, for example to
expand lymphocytes [212,213], to produce glycoproteins (in particular, antibodies) and viruses
[214-221], to cultivate hepatocytes and as extracorporeal assist devices [222-224]. Modules were
designed which distributed the main fluid flow equally to each hollow fiber in the bundle
[225]. This generated a parabolic velocity profile in the fiber lumen and resulted in uniform
shear stress for the attached cells, which was directly proportional to the intracapillary flow
rate [211,212]. Cell adhesion was enhanced by pre-coating the hollow fibers with one or even
more extracellular matrix proteins such as fibronectin or collagen [226].
The use of hollow fiber bioreactors to produce clinically relevant numbers of MSCs (total cell
yields between 108 and 109 cells) has been reported in numerous studies [227]. These cell
amounts are sufficient for autologous and selected allogeneic therapies. Exemplarily, we
would like to refer to serum-supplemented productions recently performed with the FiberCell
System (FiberCell Systems, max. growth surface of 2.5 m2) and the Quantum Cell Expansion
System (Caridian BCT, maximum growth surface of 2.1 m2). The articles describe expansion
of MSCs isolated from human bone marrow and placenta over a few weeks [210,228-230].
Nonetheless, hollow fiber bioreactors and fixed bed bioreactors subsequently described are
restricted in scalability. They both have limitations in that their nutrient and oxygen gradients
in culture restrict the length of the fiber and height of the fixed bed. The biggest challenge,
however, for both reactor types is posed by cell harvest.
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3.7. Single-use versions of fixed bed bioreactors and MSC expansions
Initial work with fixed bed bioreactors (also referred to as packed bed bioreactors) and
mammalian cells started in the 1950s. In fixed bed bioreactors cells are immobilized on or
encapsulated in a stationary matrix consisting of particles densely packed in a cylindrical
vessel. Several types of particles have been used to date: Macro-porous microcarriers, porous
ceramic beads, porous glass beads, glass fibers, polyester discs, alginate beads and hydrogels
[62,231-236]. The culture medium is perfused through the bed of the bioreactor and supplies
cells with nutrients while removing undesired metabolites. For this purpose, either an external
medium reservoir is used or the culture medium is circulated in an internal loop. When fixed
bed bioreactors are run in continuous perfusion mode, cell densities of around 5108 cells
mL-1 can be achieved. Knowledge about configurations of fixed bed bioreactors and their
bioengineering characteristics was summarized by Warnrock et al. [232].
Fixed bed bioreactors have been successfully employed in different investigations with
primary cells, such as bioartifical liver support systems and stem cell expansions. It is a well-
known fact that the company Pluristem Therapeutics, a leading developer of placenta-based
cell therapeutics, uses reusable fixed bed bioreactors (PluriX 3-D bioreactors) in combination
with Fibra-Cel® disks. Fibra-Cel® disk carriers are characterized by high porosity and com‐
posed of two layers of non-woven polyester and polypropylene [236,237]. These fiber carriers
also form the fixed bed in Eppendorf`s single-use version of the BioBLU® bioreactor, which is
obtainable up to a vessel volume of 5L. When pre-loaded with 150 g of Fibra-Cel® disks, 0.12
m2 of effective surface area per gram of disks is provided. The largest single-use fixed bed
bioreactor is Pall`s Integrity™ iCELLis™ bioreactor, which has a maximum growth surface of
500 m2 and a fixed bed made from polyethylene terephthalate microfibers [238]. But as in the
case of the BioBLU® SU bioreactor, no reviewed literature about MSC cultivation in the
Integrity™ iCELLis™ was found at the time of writing, with the exception of an mL-scale
application in which a single-use fixed bed bioreactor was used. This concerned a syringe-like
fixed bed bioreactor for the cultivation of implantable immortalized hMSCs expanded on
alginate beads and applied in cell therapy trials for stroke treatment [1,239].
4. Scale up of MSC cultivations: General considerations
In planar cultures, the growth of the adherent cells has to date been limited by the available
growth surface area, which is determined by the geometry of the cultivation vessel. Scaling
up of planar static cultures is therefore realized by increasing the growth surface (linear scale-
up), either by working with several bioreactors in parallel and/or using multilayer systems.
However, as already pointed out in Section 3, with an increasing number of layers and/or
bioreactors the risk of contamination and vessel-to-vessel variance rises. It is assumed that lot
size of planar culture systems are capped at 1-4 1011 cells, whereby lot sizes of > 1 1011 cells are
not readily achievable without massive automation and parallel processing [174].
The available growth surface area also limits the lot sizes in dynamic parallel plate, hollow
fiber bioreactors and fixed bed bioreactors, whereas concentration and temperature gradients
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are less likely in these systems because of the convective transport. Due to the limited engi‐
neering data available for these systems, no systematic scale-up studies have been published
so far and scaling-up is mainly realized using trial-and-error methods. In contrast, several scale-
up rules have now been accepted for stirred bioreactors which is why the main focus of the
following is on this bioreactor type. Since it is not possible to simultaneously maintain identical
operational characteristics such as mixing time, power input, impeller speed, carbon dioxide
removal and oxygen mass transfer over the different scales, the most important factor(s) has
(have) to be identified.
In biopharmaceutical production processes, the impeller tip speed (utip) is a frequently used
scale-up criterion [240,241], which is directly proportional to the impeller diameter and the
rotational speed. Typically, the impeller tip speed correlates well with the maximum fluid
velocities, and consequently, the maximum shear stresses, as long as low aeration rates are
used. Otherwise, local shear stresses from rising bubbles and/or bursting bubbles at the liquid
surface may exceed impeller-induced shear by several orders of magnitude [242]. Based on
model devices, non-lethal responses of hMSCs on shear stresses, including changes in gene
expression, signaling pathways and morphology as well as cell differentiation, have been
reported over a wide range of shear from 0.01 to 5 Pa [138,145,146,152,243], depending on
the cell source and donor as well as the experimental setup (used device, exposure time,
medium etc.).
However, the impeller tip speed does not account for the actual impeller type nor volume
changes during the process (e.g. by feeding or medium exchange). Particularly at larger scales,
heterogeneity in the culture environment due to gradients in dissolved gases and metabolites
can become an issue. Another possible scale-up criterion is the mixing time [244]. Based on the
turbulence theory, the mixing time was suggested to be independent of impeller type and was
found to correlate with specific power input and geometrical parameters such as the impeller
and vessel diameter and the filling height, which is valid for single impellers in draw and fill
mode as well as multi-stage impellers [245]. In comparative studies with different stirred
single-use bioreactors, mixing times of between approximately 44 s and 86 s for a constant tip
speed of 0.5 m s-1 were found [246]. In single-use bioreactors there is still a lack of systematic
comparisons of mixing that take geometric parameters into account. Furthermore, it should
be emphasized that keeping mixing time constant during scaling-up results in significant
increases in specific power input at larger scales [247,248].
For cells growing in suspension, the most frequently used scale-up criterion is the specific
power input, which can be predicted from the impeller power number (Ne) according to Eq.
9, where ρfl, nR, dR and VL represent liquid density, the impeller speed, the impeller diameter
and the liquid volume respectively.
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The power number is specific for each impeller type and depends on the Reynolds number
(Re), which was introduced in Section 2.2. In general, radial flow impellers exhibit greater
power numbers than axial flow impellers, which therefore need to rotate more quickly in
order to achieve the same power input (see Eq. 11). Reported power numbers for stirred
single-use bioreactors range from 0.3 (Mobius®  CellReady 3L) to 4.2 (Mobius®  CellReady
50/200L),  whereas  the  UniVessel  SU 2L with two segment  blade impellers  has  a  power
number of 1.1 [249].
For microcarrier-based processes, suspension criteria (NS1 and NS1U) have been proposed for
scaling-up, since they provide effective use of the available growth surface of the microcarri‐
ers. Both suspension parameters, which describe the impeller speed required to bring solid
particles (the microcarriers) into suspension, were introduced more than 50 years ago
[250-252], although their potential for microcarrier-based stem cell expansions and their
scale-up was only reported quite recently [119]. The NS1 criterion displays the impeller
speed at which all particles are just fully suspended, whereby a homogeneous dispersion of
all microcarriers is not a necessary consequence. The NS1U criterion is its lower limit and thus
the impeller speed required to locate the particles at the bottom of the bioreactor with none
of them at rest. Comparing different stirred SU bioreactors from small to pilot scale, the low‐
est impeller speeds, and, thereby power inputs required to lift up polystyrene-based micro‐
carriers with solid fractions of up 0.2 % were found in the Mobius® CellReady bioreactor
[182]. However, the suspension criteria also strongly depend on the microcarrier type used.
Thus, they should be determined as part of process development for each individual process
(see also Section 5.3).
Other agitation-related scale-up factors such as the Reynolds number or Kolmogorov’s mi‐
croscale of turbulence are more seldom used in scale-up studies. Because of the low oxygen
demands of hMSCs (1.2-3.810-17 mol oxygen s-1 cell-1) [253,254] and the relatively low cell
density, the volumetric oxygen demand can often be covered by surface aeration. Therefore,
scale-up factors related to oxygen mass transfer, such as the specific oxygen transfer coeffi‐
cient (kLa), are also considered to be less important. However, they may increase in impor‐
tance at increasing scales and higher cell densities.
5. A new scale-up approach for expanding hMSCs
5.1. Motivation
In this section, we introduce a new scale-up approach and show its suitability for rapid and
efficient expansion of hADSCs (Figure 7 A) and hBM-MSCs (Figure 7 B). Both cell types are
of therapeutic interest as the increasing number of clinical trials presented on www.Clinical‐
Trials.gov indicates. There is no doubt that alternatives to planar systems are required. Al‐
though, vessel versions with 10-or 40-layer units providing cell yields between 2⋅108 and
1⋅109 cells [31] have been established, a consistently high cell quality at high cell numbers is
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difficult to ensure. This explains the shift to suspension cultures, particularly using micro‐
carriers and stirred instrumented bioreactors, when scalable hMSC production is the focus.
Our scale-up strategy (Figure 7), which was aimed at cell yields around 1⋅1010 hMSCs and
expansion factors exceeding 30, is based on two pillars: (i) screening studies performed in
Corning spinners (Figure 7 C) at mL-scale and (ii) bioengineering investigations carried out
for the spinner system and the pilot bioreactor system chosen (Figure 7 D and Figure 7 E).
The bioengineering studies of both cultivation systems included CFD simulations and result
verification by Particle Image Velocimetry (PIV). Their aim was to predict fluid flow pattern
and fluid flow velocities to enable calculation of local shear stress distributions, turbulent
dissipation rates and Kolmogorov`s micro-scales.
Together with the microcarrier distributions, these parameters were considered in order to
predict optimum impeller speeds while avoiding high shear stresses, which finally result in
cell differentiation or even cell death. As proposed by Kaiser et al. [255] the suspension crite‐
ria NS1 and NS1U were employed to transfer the process from 100 mL to 35 L and 50 L work‐
ing volumes, respectively.
It is worth mentioning that all the cultivations ran between 6 and 9 days and were executed
in fed batch mode at low-serum conditions. Reducing the serum-content in the culture me‐
dium or using serum-free or chemically defined culture media contributes to process cost
reductions, and simplifies downstream processing and product approval [65,256]. The two
cell types used were provided by the Lonza Cologne GmbH, Germany. They were each cry‐
opreserved (second passage, population doubling level of 10) and originated from a single
consenting, informed donor. In all hMSC production processes, daily sampling and sample
analyses in accordance with the descriptions of Schirmaier et al. [196] and Jossen et al. [197],
were executed. In addition to the determination of cell density, viability, concentrations of
glucose, lactate, glutamine and ammonia, flow cytometric and apoptotic investigations were
performed.
5.2. Investigations at mL-scale
In total, seven different culture media from different suppliers with varying contents of FBS
(0-10 %) and six different microcarrier types (different densities and diameters) were used in
the comprehensive spinner screening. The results for both hMSC types (cell growth, substrate
and metabolite courses and cell expansion factors) achieved in the Corning spinners and 2-
layer Corning CellSTACKs, were compared with those of cultivations in standard DMEM
(Dulbecco’s Modified Eagle Medium) with 10 % FBS. While propagating the cells at micro‐
carrier solid fractions of 1.43 % (polystyrene matrix-based microcarriers) and 0.3 % (gelatin
matrix-based microcarriers) over 6 days, the culture broth was stirred intermittently or
continuously at 60 rpm (37°C, 5 % CO2 and 80 % humidity). This impeller speed had been
previously determined in spinner experiments aimed at cell yield optimizations in standard
DMEM medium containing 10 % FBS. Serum-free expansion (0 % FBS) of both cell types was
possible, but the expansion factors achieved were below 10 and regarded as insufficient. Lonza
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stem cell medium provided the most promising results and allowed satisfactory growth at low
serum-content (5 % FBS) and at continuous stirring, when hADSCs were propagated on the
polystyrene carriers and hBM-MSCs expanded on the gelatin carriers with the lower density.
A further improvement in the cell expansion factor (60 instead of 40) and the maximum cell
yield (1⋅108 cells instead of 4⋅107 cells) was achieved by: (1) modifying the Lonza stem cell
Figure 7. Our expansion approach with (A) DAPI staining of microcarriers realized in hADSC expansions with poly‐
styrene-based carriers in the BIOSTAT® CultiBag STR 50L on cultivation day 7 (0.71 % solid fraction), (B) DAPI stain‐
ing of microcarriers realized in hBM-MSC expansions with gelatin-based carriers in the BIOSTAT® CultiBag on
cultivation day 7 (0.21 % solid fraction), (C) 125 mL spinner flasks equipped with top-mounted blade impeller with
diameter of 41.5 mm and operated with 100 mL working volume, (D) BIOSTAT® CultiBag STR 50L during one experi‐
mental run and (E) its polyethylene multilayer bag in which two 3-segment blade impellers with a diameter of 143
mm, a microsparger, and single-use pH-and DO-probes were implemented. The bag have being fixed and shaped by a
stainless steel support container. Scale bars in (A) and (B) indicate 1000 m.
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medium and realizing one single feed (with a feeding solution) instead of performing a single
50 % medium exchange between day 3 and 4, (2) increasing the inoculum density and (3)
increasing the microcarrier concentration.
The transfer of fluid flow at the optimum cultivation conditions found in the spinner presup‐
posed CFD modeling. To date, several studies have demonstrated the usefulness of CFD in
analyzing fluid dynamics at both micros-and macroscopic levels in stem cell bioreactors [132,
255,257]. We modeled the fluid flow inside the Corning spinner flask by using the finite volume
solver Fluent from ANSYS (ANSYS Inc., version 14.0, USA) and calculated the three local
velocity gradients as well as their magnitude. For more detailed information the interested
reader is referred to Kaiser et al. [255]. As exemplarily shown in Figure 8 for 60 rpm and 100
mL working volume, the flow in the spinner flask was primary tangential with low axial and
radial velocity components. Due to the wide impeller blade and the absence of baffles, the
observation that the tangential velocity was the highest velocity component comes as no
surprise. As also expected the velocities were highest at the edges of the impeller blade as well
as at the tips of the impeller bars and correlated directly with utip. In contrast, the lowest
velocities were determined below the impeller and near the vessel wall. It was also found that
sedimentation and agglomeration of the microcarriers were most likely to occur below the
impeller bar. This finding was also confirmed by the microcarrier distribution in the spinner
flasks, which is depicted in Figure 9. Furthermore, at 60 rpm and 100 mL working volume the
mean local shear stress level (τnt) was 4⋅10-3 N⋅m-2 and the maximum value was estimated to
be 0.2 N⋅m-2. The mean turbulent energy dissipation rate (ε) was 1.1⋅10-3 m2⋅s-3 and the
maximum turbulent energy dissipation rate was about 10 times higher. The mean and
minimum Kolmogorov’s microscales of turbulence were 60 μm and 191 μm, respectively.
However, we would like to point out that Kolmogorov’s theory is only valid for high turbu‐
lence (Re ≥ 104) and because Re was 1722 under the process conditions used, the Kolmogorov’s
values estimated should be viewed critically.
As various mathematical models are available for the simulation of fluid flow in a stirred
bioreactor system, the CFD-predicted fluid flow pattern and fluid velocities need to be veri‐
fied. For this purpose different analytical methods can be used, PIV representing one of
those most frequently applied. Its advantages are given by the contactless measuring princi‐
ple, in which a 1 mm thick laser sheet is generated by a double-pulsed Nd:YAG laser (wave‐
length λ=532 nm). By adding rhodamine-coated fluorescent particles to the reactor volume,
the fluid flow can be visualized and fluid velocities can be measured by recording a set of
double images with a small time offset (cross correlation). More detailed representations of
this method can be found in [255] and [132]. As exemplarily shown in Figure 8 C for the
Corning spinner flask in two vertical positions (below and above the impeller), the CFD-pre‐
dicted tangential fluid velocities are in good agreement with the PIV-measured data with
relative deviations below 7 %. These results illustrate that the fluid velocities are well-cap‐
tured by the CFD model and the model is therefore suitable.
In order to determine the microcarrier distribution, the single-phase model was extended by
an additional Eulerian phase (Euler-Euler RANS approach), which also takes the microcarrier
into account as a solid phase [255]. Figure 9 illustrates the microcarrier distribution of the
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polystyrene-type carrier at stirrer speeds below and similar to the NS1U criterion. As previously
mentioned, the microcarrier sedimentation and agglomeration is most likely to be found below
the impeller bar, especially at lower impeller speeds (N < NS1U and NS1). At these conditions,
the cells on the microcarriers, particularly those in the centre of the deposit are not well
supplied with nutrients and oxygen. Thus, a mass transfer limitation and a gradient formation
can occur, which may have a negative effect on cell quantity and quality. Both limitations can
be reduced, or even prevented by increasing the impeller speed. However, this involves raising
the specific power input in the bioreactor, thereby increasing the shear stress acting on cells.
Consequently, impeller speeds are required that guarantee sufficient mixing at power inputs
tolerated by cells without differentiation or dying off. Process conditions which fulfill these
requirements are obtained at specific suspension criteria (NS1 and NS1U). By increasing the
impeller speed to the NS1U criterion, the deposit directly below the impeller bar can be reduced
to a state in which only a few microcarriers are situated directly below the impeller, with none
of them at rest (local microcarrier movement along the bioreactor bottom). This can be seen in
Figure 9 C, where a decrease in the local volume fraction of the microcarriers from around 0.4
% to 0.1 % below the impeller bar is shown. Compared to the NS1 criterion, where the micro‐
carriers are not in contact with the reactor bottom for more than one second, the NS1U provides
more gentle conditions for the cells. However, both criteria strongly depend on the character‐
istics of the microcarrier type (density, diameter, porosity) and the bioreactor (dimension/
configuration). Accordingly, the suspension criteria needed to be determined for each
microcarrier and bioreactor used in the expansions.
The NS1U and NS1 criteria determined for the polystyrene matrix-based microcarriers (solid
fraction: 0.25 – 2 %) were in a range of 34 – 50 rpm and 44 – 61 rpm respectively, and for the
gelatine matrix-based microcarriers (solid fraction: 0.25 – 1 %) 59 – 79 rpm and 80 – 93 rpm
respectively. Indeed, the NS1u criterion was always achieved at 20 ± 4 % lower impeller speeds,
which indicates reproducible determinability of the NS1U criterion.
Figure 8. Fluid flow conditions in the Corning spinner flask at 60 rpm and 100 mL working volume. The fluid flow is
presented as a combined vector-contour plot along a horizontal plane (A) and as normal contour plot along a vertical
plane (B). The graph (C) illustrates the good agreement between the CFD-predicted (-) and PIV-measured (•) fluid ve‐
locities along the radial coordinates in two vertical positions below and above the impeller bar.
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Figure 9. CFD-predicted, and experimentally observed microcarrier distributions for the Corning spinner flask at stir‐
rer speeds below (A) and similar to (B) the NS1U criterion. Good agreement is achieved between the CFD-predicted and
experimentally observed microcarriers distributions. (C) The graph illustrates the reduction of the microcarrier volume
fraction below the impeller from 0.4 % to 0.1 % by increasing the impeller speed to the suspension criterion (NS1U).
5.3. Investigations at L-scale
Generation of hMSCs in clinically relevant numbers requires an increase in growth surface as
well as in a bioreactor`s working volume. Because Sartorius`s BIOSTAT® CultiBag STR family
is commercially available up to m3 scale, and bioengineering data are available for the 50 L,
200 L, 1 m3 and 2 m3 versions [194,258], we decided to realize the process scale-up in the
BIOSTAT® CultiBag STR 50L. For the preliminary investigations at mL-scale, which demon‐
strated the usefulness of the suspension criteria for the microcarrier-based stem cell cultivation
[255], NS1U and NS1 were experimentally determined for the BIOSTAT® CultiBag STR 50L in a
first step. For this purpose a Plexiglas model with the dimensions of the bag holder (which
allowed visual evaluation of the suspension criteria) was used instead of the flexible multilayer
bag (Figure 7 E). More detailed information on the PIV measurement principle applied is given
by Schirmaier et al. [196].
In order to achieve the target cell yields, the growth surface was increased accordingly,
whereby microcarrier solid fractions of 0.20 – 1.25 % (polystyrene microcarriers) and 0.1 – 0.4
% (gelatin matrix-based microcarriers) were employed in the suspension studies. The impeller
speeds required to ensure the suspension criteria (NS1U, NS1) were in a range of 40 – 66 rpm
and 50 – 77 rpm for the polystyrene microcarriers. In the case of the gelatin matrix-based
microcarriers, values ranging from 52 – 68 rpm and 63 – 79 rpm were required. Nevertheless,
for both hMSC types a comparable correlation (20 ± 5 %) between the suspension criteria in
the spinner flask and the BIOSTAT® CultiBag STR 50L was detected. Based on the estimated
impeller speeds, single-and multi-phase CFD simulations were performed in order to inves‐
tigate the fluid flow (flow pattern, fluid velocities) as well as to predict the specific power
inputs and the shear gradients in the BIOSTAT® CultiBag STR 50L. As illustrated in Figure 10
A and B the fluid flow in the BIOSTAT® CultiBag STR 50L was primary axial with two flow
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loops, whereby the axial fluid velocities at the bottom of the bioreactor enabled the microcar‐
riers to swirl up. Due to the distinctive axial flow characteristics, which were caused by the
two 3-segment blade impellers, as well as the relatively high axial velocities near the reactor
bottom (0.04-0.1⋅utip), the microcarriers swirled up even at relatively low impeller speeds.
Similarly, the prevalence of the axial fluid flow was obvious from PIV measurement data,
where a good agreement between the CFD-predicted and the PIV-measured fluid velocities
(relative deviation < 10 %) was achieved [258].
Figure 10. Fluid flow conditions and required specific power inputs for the NS1U criterion in the BIOSTAT® CultiBag
STR 50L. The contour and vector-plots are given along the mid-reactor plane. The contour plot (A) illustrates that the
induced fluid flow in the BIOSTAT® CultiBag STR 50L is primary axial with two flow loops, whereby the axial fluid
velocities (B) impinge on the reactor bottom and enable the microcarriers to swirl up. (C) The specific power inputs
required to fulfill the NS1U criterion are in a comparable range for both the spinner flask and the BIOSTAT® CultiBag
STR 50L.
The suspension studies showed that the number of impellers has no significant effect on the
suspension criteria. Thus, fed batch strategies can be realized which start with low working
volumes and where only the lower impeller is immersed in culture medium. As is depicted in
Figure 10 C, the CFD-predicted specific power inputs for the NS1 criterion at different micro‐
carrier solid fractions in the BIOSTAT® CultiBag STR 50L were slightly higher (20 – 180 %) than
in the spinner flask. However, the specific power inputs required were in the same magnitude
and appropriate for the microcarrier solid fraction range desired. A closer look at the local
maximum shear stress levels (1.06 N⋅m-2) at 60 rpm (0.4 % and 0.2 % solid fraction of poly‐
styrene and gelatine matrix-based microcarriers respectively) also revealed a slightly higher
stress on the cells grown in the BIOSTAT® CultiBag STR 50L. However, these higher shear
stresses occured only in a low percentage (3.15⋅10-5 %) of the volume and the cells were only
exposed to these conditions for a short time. Beyond that, the local mean shear stress levels
were in a range comparable to that in the spinner flask, which indicates a broader distribution
of the local shear stresses in the BIOSTAT® CultiBag STR 50L [196,258]. The fluid flow in the
BIOSTAT® CultiBag STR was more turbulent (Re=13591 – 26817) than in the spinner flask,
which allowed a more reliable evaluation of Kolmogorov`s microscales under the conditions
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investigated. Compared to the diameters of the microcarriers, the predicted minimal (14 – 19
μm) and mean (197 – 268 μm) Kolmogorov`s microscales indicated that some turbulent eddies
were in the same order of magnitude. However, the stem cells were only in contact with the
critical turbulent eddies (2/3⋅lλ < d < lλ) for a restricted (short) time and cell death was not
detected until day 8 of the cultivations.
Figure 11. Flow chart showing the main steps of hBM-MSC expansions at pilot scale. hBM-MSCs from the working cell
bank (second passage) were used to generate the seed inoculum (2-layer CellSTACKs®, 1272 cm2 growth surface) with‐
in 4 days. After seed inoculum harvest and microcarrier preparation had been carried out according to the manufac‐
turer`s recommendations, a 4-hour cell attachment phase was realized by transferring the inoculum to a BIOSTAT®
CultiBag RM 20L basic (Sartorius Stedim Biotech) containing the equilibrated gelatin microcarriers. The bag was
placed in an incubator and kept stationary to promote attachment of cells. For subsequent stem cell expansion, the mi‐
crocarrier cell suspension was transferred to the BIOSTAT® CultiBag STR 50L. Pilot runs were started with 35 L work‐
ing volume at 37 °C, a DO value above 20 %, and a maximum air flow rate of 0.03 vvm. pH ranged between 7.2 and
7.3, and impeller speeds were between 50 rpm and 66 rpm. After cell separation, harvest and purification, the cells
were frozen for long-term storage (-196°C).
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Based on the CFD-predicted engineering parameters and the optimal cultivation conditions
derived for the two hMSC types, serum-reduced expansions at 35 L for the hADSCs and 50 L
for the hBM-MSCs were carried out. Because of the higher clinical relevance of the hBM-MSCs,
only one run (fed batch mode with 50 % medium exchange on day 4) was realized for the
hADSCs [196], whereas an optimized feeding procedure was developed for the hBM-MSCs.
The main process steps of the successful hBM-MSC-based feeding procedure, which is in
agreement in the main lines for the 35 L hADSC production, are shown in Figure 11. A detailed
description of the hADS expansion, where the multilayer flask-based seed inoculum produc‐
tion was omitted, can be found in [196].
For both hMSC types comparable cell growth was achieved in both the spinner flask and the
BIOSTAT® CultiBag STR 50L runs (Figure 12 A and B). For the hADSCs, peak viable cell density
in the spinner flask was 2.92⋅105 cells⋅mL-1 and 3.0⋅105 cells⋅mL-1 in the BIOSTAT® CultiBag
STR 50L. The hADSCs grew with a growth rate of 33.6⋅10-3 h-1 in the spinner flask and
30.4⋅10-3 h-1 in the BIOSTAT® CultiBag STR 50L, which corresponds to doubling times of 20.6
h and 22.8 h respectively [196]. By realizing the optimized feeding approach, the peak viable
cell densities of the hBM-MSCs were around 2 to 2.4 times higher (6.8⋅105 cells⋅mL-1 in the
spinner flask and 7.2⋅105 cells⋅mL-1 in the BIOSTAT® CultiBag STR 50L) compared to the
hADSC expansions. The expansion factor was 39.6 ± 3.6 in the spinner flask and 51.5 ± 4.9 in
the BIOSTAT® CultiBag STR 50 L. These are the highest expansion factors so far reported for
serum-reduced hBM-MSC productions [64,191,192]. The hBM-MSCs grew with similar growth
rates (μ) to the hADSCs (34.8⋅10-3 h-1 in the spinner flask and 30.4⋅10-3 h-1 in the BIOSTAT®
CultiBag STR 50L), whereby the peak viable cell densities were achieved one day earlier. Cell
growth at the end of the cultivations was restricted by the limited microcarrier growth surface.
Figure 12. Courses of viable cell densities of hADSCs (A) and hBM-MSCs (B) in the BIOSTAT® CultiBag STR 50L and
the control spinner flasks. (A) hADSC cultivation was performed at 35 L scale (50 % medium exchange on day 4). (B)
Optimized hBM-MSC cultivation was performed at 50 L scale (feed on day 5).
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During all the cultivations the expanded stem cells maintained their stem cell properties and
qualities. Figure 13 shows the flow cytometric analysis of hBM-MSC samples. The specific
surface markers (CD34-, CD45-, CD73+, CD95+, CD105+) were determined according to the
recommendations of the ISCT [25]. Comparable results were also found for the hADSC
cultivations in the BIOSTAT® CultiBag STR 50L [196].
Figure 13. Flow cytometric analysis (FACS) of specific surface markers performed with hBM-MSC samples before
(seed inoculum) and at the end (after harvest) of the expansion procedure. Positive surface markers: CD73+, CD90+,
CD105+. Negative surface markers: CD34-, CD45-.
6. Conclusion
The potential of MSCs is undoubted and explains the increasing clinical interest in high cell
yields for therapy approaches. The successful expansion of MSCs to clinically relevant
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numbers and qualities strictly depends on the bioreactor type and its bioengineering param‐
eters, in particular the fluid flow and shear stress. Non-instrumented multilayer vessels
normally used for MSC expansion may be advantageously replaced by instrumented dynamic
single-use bioreactors. Nowadays, users already have access to stirred, wave-mixed, parallel
plate, hollow fiber and fixed bed versions, which confirm the applicability of these bioreactor
types for different MSC expansion studies.
For autologous therapies, stirred singles bioreactors operating at benchtop scale and providing
yields of 1⋅109 MSCs after harvest from microcarriers have proven themselves. Availability of
bioreactor CFD models has supported the determination of bioengineering parameters as well
as prediction of fluid flow and shear stress. Moreover, knowledge of fluid flow patterns and
velocities, local shear stress distributions, turbulent dissipation rates and Kolmogorov`s
microscales has contributed to an increase in expansion efficiency and supported avoidance
of cell differentiation. Together with microcarrier distribution, these parameters can also be
used to rapidly and successfully transfer hADSC-and hBM-MSC-based expansions from mL-
up to pilot scale. They provide the basis for the production of MSC-derived allogeneic cellular
therapeutic products, for which trillion of cells will be required annually.
Stem cell therapeutics are now in transition from development to clinical applications. A large
number of stem cell therapeutics are in the clinical pipeline or already in clinical trials [14,31].
This requires clinical-grade bioprocessing and scale-up approaches for expansion of MSCs
from human sources. However, the application of MSCs is hampered by a number of facts
intrinsic to these cells. As summarized by Wuchter et al. [44], MSCs vary in composition, their
cell source (e.g., bone marrow, adipose tissue and cord blood) and the protocols applied for
cell isolation and expansion. The available markers are not regarded as sufficient for compar‐
ison of data and quality control. Therefore, experimental and clinical data from different
laboratories involved in multicenter trials are difficult to compare. Criteria important for
quality control include the immunophenotype of the cells, composition of the culture medium
and the risk of malignant transformation, as well as the aging and the immunosuppressive
potential of the manufactured MSCs [44].
Stem cells could be used in cell therapy either as mass-produced allogeneic cells or autologous
cells [31]. In both cases scalable, controlled bioprocessing techniques are required. Establishing
these processes is complicated by the fact that guide lines developed for the production of
biopharmaceuticals (e.g. monoclonal antibodies) are generally unsuitable for cell therapeutics.
Whereas in bioproduction the quality of the product is of major concern and the cells are
typically discarded after production, for cell-based therapies the cell-specific properties are
essential and require highly specific processes. An overview of the clinical and regulatory
pathways for stem cell-based therapies and recent developments is given by [13,31,44].
Future availability of serum-free or even chemically defined culture media and microcarriers
allowing simple cell harvest (e.g. after temperature-or pH-shift) and reproducible production
will simplify the approval of cell therapeutics. Moreover, it will provide new findings in
respect of operational demands and shear stress sensitivity of MSCs.
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Abbreviations
1-D One-dimensional
2-D Two-dimensional
3-D Three-dimensional
CD Cluster of differentiation (e.g. CD105)
CFD Computational Fluid Dynamics
CHO Chinese hamster ovary
DAPI 4’,6-diamidino-2-phenylindole
DMEM Dulbecco’s Modified Eagle’s Medium
DO Dissolved oxygen
FBS Fetal bovine serum
FCS Fetal calf serum
FGF Fibroblast growth factor
GMP Good Manufacturing Practice
hADSC Adipose tissue-derived human mesenchymal stem cell
hBM-MSC Bone marrow-derived human mesenchymal stem cell
hMSC Human mesenchymal stem cell
hMSC-TERT Telomerase-immortalized human mesenchymal stem cells
ISCT International Society for Cellular Therapy
MSC Mesenchymal stem cell
PIV Particle Image Velocimetry
RANS Reynolds-averaged Navier-Stokes
Symbols
Latin symbols
Symbol Unit Description
b m Width of flow chamber
dR m Impeller diameter
DR m Vessel diameter
F m3 s-1 Flow rate
h m Height of flow chamber
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Symbol Unit Description
ISF s-1 Integrated shear factor
lKol m Turbulent Kolmogorov microscale
kLa h-1 volumetric mass transfer coefficient for oxygen or CO2
nR s-1 Rotational speed
Ne - Newton-Number
NS1 / NS1U rpm Suspension criteria, describing the microcarrier distribution at just fully
suspended conditions (NS1) and below (NS1U)
P W Power input
P/V W m-3 Specific volumetric power input
Re - Reynolds-Number
utip m s-1 Maximum rotating velocity
U m s-1 Flow velocity
VL m3 Liquid volume
Greek symbols
Symbol Unit Description
αp - Solid volume fraction
γ s-1 shear rate
ε m2 s-3 Turbulent energy dissipation rate
ηfl Pa s Dynamic viscosity
λ nm Wavelength
μ h-1 Specific growth rate
ν m2 s Kinematic viscosity
ρfl kg m-3 Liquid density
τ Pa Shear stress
τnt Pa Local shear stress
τw Pa Wall shear stress
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